ParagonCare (ASX:PGC), Metcash Limited (ASX:MTS) and Redox Limited (ASX:RDX) operate across three different parts of the Australian distribution and wholesale market. ParagonCare supplies pharmaceuticals, healthcare consumables and medical technology, Metcash supports independent food, liquor and hardware retailers, while Redox distributes chemicals, ingredients and raw materials across multiple industrial and consumer markets.

Their latest disclosures highlight the importance of working-capital management, customer Credit quality, freight costs and operating margins in distribution businesses. ParagonCare is focused on cash conversion and reducing Leverage following a customer credit issue, Metcash is working through cost Inflation and technology investment, while Redox is expanding in North America and retaining balance-sheet capacity for acquisitions.

2026 Distribution Context

Distribution companies sit between suppliers and end customers, meaning Earnings depend on more than sales volumes alone. Inventory needs to be purchased and stored, customer receivables must be managed, and freight and labour costs need to be recovered through pricing or improved product mix.

Higher financing costs make this particularly relevant for businesses carrying large amounts of working capital. Companies with elevated inventory or customer credit exposure can face additional interest and Liquidity pressure when cash remains tied up for longer periods.

Demand also differs materially across end markets. Grocery distribution can be comparatively defensive, healthcare is supported by hospital, pharmacy and medical demand, while chemicals distribution follows activity across manufacturing, agriculture, mining, nutrition and other industries.

ParagonCare (ASX:PGC)

Business Profile

ParagonCare has developed into a broad healthcare distribution group following its combination with CH2 Holdings. The group operates across pharmaceutical wholesale, medical technology, healthcare consumables, contract logistics, clinical Manufacturing and selected Asian healthcare markets.

Its Australia and New Zealand segment contains the large pharmaceutical wholesale operation alongside medical technology and related healthcare activities. The Asian Business provides additional exposure to medical devices and aesthetics distribution across South-East Asian markets.

FY2026 Performance

For the year ended 30 June 2026, ParagonCare reported Revenue of approximately AUD 3.7 billion and underlying EBITDA of AUD 97.2 million.

Underlying net profit after tax was AUD 26.0 million, while the statutory result was a net loss of AUD 16.0 million.

The difference between underlying and statutory earnings was heavily influenced by the Infinity Retail Pharmacy Group exposure. ParagonCare recognised a lifetime expected credit loss expense of AUD 34.9 million in FY2026 after the customer entered external administration.

The Australia and New Zealand business remained the largest contributor, while Clinical Manufacturing delivered additional growth. In Asia, the group continued to expand through a combination of organic activity and acquisitions, although the broader product mix affected segment margins.

Cash Flow and Balance Sheet

ParagonCare generated operating cash of AUD 29.1 million during FY2026, while net working Capital stood at AUD 94.1 million.

Net Debt ended the year at approximately 2.5 times underlying EBITDA. This places debt reduction and cash conversion among the most important near-term financial priorities.

No FY2026 Dividend was declared. Management indicated that capital returns would be reconsidered around the FY2027 half-year period, making balance-sheet progress relevant to any future decision.

Integration and Expansion

The group completed its post-merger integration programme during FY2026 and reported that targeted synergies of approximately AUD 12 million had been achieved.

ParagonCare also continued expanding through acquisitions, including Haju Medical in Indonesia and Fisher Biotec in Australia. These transactions broaden the company's exposure to specialised healthcare distribution and selected growth markets.

Risks

Customer credit remains a significant risk for a wholesaler because large receivable balances can create material losses when a customer fails.

Leverage is another consideration following Acquisition activity. The company needs to convert revenue and underlying earnings into cash while reducing debt.

Supplier relationships can also affect the business, particularly in medical technology where manufacturers can alter distribution arrangements.

Further expansion in Asia presents opportunities but also introduces integration and margin-management requirements.

What Investors May Monitor Through the Rest of 2026

Further recovery from the Infinity exposure will remain important, together with any indication that net leverage is moving back toward lower levels.

Investors may also monitor cash conversion, Asian margins and the contribution from recently acquired businesses.

The company's FY2027 half-year update may eventually provide greater clarity on earnings, debt reduction and whether dividends are reconsidered.

Metcash Limited (ASX:MTS)

Business Profile

Metcash is a wholesale and distribution group serving independent retailers across Food, Liquor and Hardware & Tools.

The Food division supplies the IGA network and also includes foodservice and convenience activities. Liquor supports independent bottle shops and hospitality customers, while Hardware & Tools includes the Independent Hardware Group and Total Tools.

Metcash operates on an April financial year, meaning FY2026 ended on 30 April 2026 and FY2027 began in May.

FY2026 Performance

Metcash reported FY2026 group sales revenue of AUD 17.35 billion, while total sales including charge-through activity reached AUD 19.63 billion.

Underlying EBITDA was AUD 761.7 million and underlying EBIT was AUD 503.7 million. Underlying Profit after tax reached AUD 268.8 million, while statutory net profit after tax was AUD 279.1 million.

Food generated revenue of approximately AUD 10.5 billion and EBIT of AUD 261.8 million. The division continues to support independent supermarkets while also expanding its exposure to convenience and foodservice markets.

Liquor generated approximately AUD 5.4 billion of revenue and EBIT of AUD 100.1 million. Hardware & Tools produced around AUD 3.7 billion of revenue and EBIT of AUD 177.3 million, with Total Tools remaining an important component of the division.

Cash Flow and Capital Position

Operating Cash Flow reached AUD 558 million and Metcash finished FY2026 with net debt of AUD 616.6 million.

Leverage stood at approximately 1.0 times, placing the group at the lower end of its stated target range. Metcash also retained significant undrawn financing capacity.

Capital expenditure moderated to AUD 244 million as major Investment in distribution infrastructure moved beyond its peak period.

Risks

Metcash faces competition across grocery, liquor and hardware, particularly as independent retailers operate against large national chains.

Cost inflation is another risk because wholesale margins can be affected when wage, freight and operating costs rise faster than prices charged to customers.

The Program Horizon transition introduces technology and implementation risk.

Changes in tobacco sales and excise arrangements can also distort reported Food sales, making underlying category performance an important consideration.

What Investors May Monitor Through the Rest of 2026

The first FY2027 half-year result will provide a clearer indication of whether cost savings are offsetting inflation across Food and Liquor.

Hardware & Tools trading will also remain relevant as management seeks improved performance across the broader division.

Progress on Program Horizon and implementation of the first cloud-system release will be another important operational milestone.

Redox Limited (ASX:RDX)

Business Profile

Redox distributes chemicals, ingredients and raw materials into a broad range of industrial and consumer markets.

Its customers operate across agriculture, food, health and nutrition, personal care, mining, water treatment, coatings and other industries.

The company works with more than 8,700 active customers and over 1,200 suppliers, while its catalogue includes more than 5,500 stock-keeping units.

Australia and New Zealand remain the largest markets, although North America has become an increasingly important growth region.

FY2026 Performance

Redox reported FY2026 sales of AUD 1.33 billion and Gross Profit of AUD 298 million, producing a gross margin of 22.4%.

Underlying EBITDAFX, the company's preferred operating earnings measure, reached AUD 134 million.

Statutory net profit after tax was AUD 91.9 million, while underlying NPATFX reached AUD 87 million.

Australia generated approximately AUD 1.12 billion of revenue and remained the dominant market. New Zealand contributed approximately AUD 100 million.

North American revenue exceeded AUD 100 million, supported by customer wins and the introduction of additional products. The region is becoming a more meaningful part of Redox's geographical Diversification strategy.

Cash Flow and Balance Sheet

Redox generated statutory Operating Cash Flow of AUD 87.8 million and ended FY2026 with AUD 123 million of cash and no net debt.

Net Working Capital was AUD 417 million, equivalent to a substantial proportion of revenue. This reflects the inventory and receivables required to support a large distribution business.

The debt-free position provides financial flexibility despite those working-capital requirements.

Redox declared a fully franked final dividend of 6.5 cents per share. Together with the interim distribution, total FY2026 dividends were 13 cents per share.

Growth Strategy

Redox continues to expand organically while also pursuing bolt-on acquisitions that broaden product categories or geographical reach.

Management has indicated that FY2027 volumes are expected to increase by approximately 7% to 8%, with pricing potentially providing an additional contribution.

The company also intends to pursue at least one acquisition equivalent to roughly 10% of its current revenue base.

With no net debt and AUD 123 million of cash, the Balance Sheet gives management capacity to pursue transactions without immediately relying on substantial external funding.

Risks

Redox is exposed to freight and transport costs because products are sourced from a global supplier network.

Foreign exchange movements can affect purchasing costs and the translation of overseas earnings.

Commodity and raw-material pricing can also create timing differences between supplier cost movements and customer price adjustments.

Working capital remains structurally significant, while international expansion and acquisitions create execution and integration risks.

What Investors May Monitor Through the Rest of 2026

North American growth will remain one of the most important operating indicators as Redox builds scale outside Australia and New Zealand.

Investors may also monitor whether New Zealand Demand improves and whether management completes another acquisition.

Working-capital efficiency, cash generation and maintenance of gross margins will provide further information on the quality of revenue growth.

Risks to Watch

ParagonCare faces customer-credit, leverage and acquisition-integration risks. The Infinity matter demonstrated how a single counterparty can materially affect statutory earnings and cash recovery.

Metcash faces cost inflation, competition and technology-execution risks. Its broad wholesale platform provides diversification, but profitability depends on managing thin margins across large sales volumes.

Redox faces working-capital, freight, foreign exchange and acquisition risks. Its debt-free balance sheet provides flexibility, although continued expansion still requires disciplined inventory and receivables management.

Outlook Through the Rest of 2026

ParagonCare enters FY2027 with revenue of approximately AUD 3.7 billion and underlying EBITDA of AUD 97.2 million. Cash conversion, debt reduction and further recovery from the Infinity exposure will remain central to the outlook.

Metcash enters FY2027 following AUD 17.35 billion of FY2026 group sales revenue and is focused on cost reduction, technology implementation and performance across Food, Liquor and Hardware & Tools.

Redox enters FY2027 with AUD 1.33 billion of FY2026 sales, AUD 123 million of cash and no net debt. North American expansion, acquisitions and working-capital management remain the primary themes.

The three businesses therefore enter the next phase with different priorities: ParagonCare is focused on credit recovery and leverage, Metcash on cost control and operational systems, and Redox on international expansion and disciplined capital deployment.